Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Ubiquigent provides access to the necessary expertise, chemistry (recently launching DUBtarget™-001, a deubiquitylase targeted hit-finding library), high quality research tools and integrated and collaborative drug discovery services required to support our commercial and academic partners in pursuing ubiquitin system-focused drug discovery programmes, and in undertaking basic research.
Nanome has designed an innovative software solution that leverages Virtual Reality to provide scientists with an immersive tool for collaborative molecular visualization, drug discovery, and drug design. Imagine being able to invite your colleagues to an environment where you can explore, manipulate, analyze small molecules or macro-molecular structures together in 3-D. For more information please come try our software or visit www.nanome.ai
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.